Leerink Partners Initiates Coverage On 10x Genomics with Outperform Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has initiated coverage on 10x Genomics (NASDAQ:TXG) with an Outperform rating and set a price target of $35.

September 03, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has initiated coverage on 10x Genomics with an Outperform rating and a price target of $35, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $35 by Leerink Partners suggests a positive sentiment towards 10x Genomics. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100